Vivek Subbiah: Precision Medicine – This is how we eradicate cancer as we know it

Vivek Subbiah shared on X/Twitter:

“The best breast cancer clinical trial research strategy team in the universe is right here Sarah Cannon Docs. Special privilege and honor to work with this dream team on how we can help more patients with cancer!

So thankful for our breast cancer team’s support in welcoming me to my first SABCS23 meeting, cheering and inspiring me in the Tumor Agnostic session. Dr. Erika Hamilton is 100% right – breast cancer researchers are an amazing group – so many hi-fives and hugs. Precision Medicine – This is how we eradicate cancer as we know it.”

Source: Vivek Subbiah/X

Vivek Subbiah is the Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute (USA). He is the former Executive Director of Oncology Research at the MD Anderson Cancer Network and a former Associate Professor in the Department of Investigational Cancer Therapeutics at The University of Texas MD Anderson Cancer Center.

Dr. Vivek Subbiah has served as the principal investigator in over 100 phase I/II trials and co-investigator in over 200 clinical trials and is known for his leadership in several first-in-human and practice-changing studies that directly led to approvals from the FDA, European Medicines Agency, and other agencies across the world. He is an expert in tumor agnostic precision oncology and leads the BRAF and RET tissue agnostic studies to FDA approval.